Clinical Trial Update: Open-Label Study of AG10 in Patients with Cardiomyopathy [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of AG10 in patients with amyloid cardiomyopathy is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloid Cardiomyopathy

Drugs mentioned

• AG10

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloid Cardiomyopathy | Phase 2 | Status: ACTIVE_NOT_RECRUITING